HEY1 promotes the development and metastasis of osteosarcoma through CD44/EGFR/FAK pathway

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• Osteosarcoma (OS) is a prevalent and deadly bone cancer, particularly in adolescents.
• Identifying novel therapeutic targets is crucial for improving OS patient outcomes.
• Bioinformatics offers a powerful approach to discover key genes influencing cancer prognosis.

Purpose of the Study:

• To identify key genes impacting osteosarcoma prognosis using integrated bioinformatics analysis.
• To investigate the functional role of the identified oncogene, HEY1, in osteosarcoma progression.
• To elucidate the molecular mechanisms by which HEY1 influences osteosarcoma cell behavior.

Main Methods:

• Comprehensive integration of multiple OS-related databases.
• Bioinformatic screening to identify crucial oncogenes.
• Experimental validation including gene silencing (knockdown) in OS cells.
• Transcriptome sequencing and mass spectrometry to identify molecular interactions.
• In vivo validation using animal models.

Main Results:

• HEY1 was identified as a crucial oncogene significantly overexpressed in OS tissues and cells.
• HEY1 silencing markedly inhibited osteosarcoma cell proliferation.
• HEY1 interacts with CD44, and regulates the EGFR-FAK pathway via CD44.
• HEY1 influences the biological phenotype of OS cells through this pathway.
• In vivo studies confirmed the impact of HEY1 on OS progression.

Conclusions:

• HEY1 is significantly overexpressed in osteosarcoma and plays a critical role in its prognosis.
• HEY1 acts as an oncogene by regulating the CD44-mediated EGFR-FAK pathway.
• Targeting HEY1 presents a promising therapeutic strategy for osteosarcoma.